Arixa Pharmaceuticals

Arixa Pharmaceuticals is developing oral antibiotics to combat resistance in Gram-negative bacteria. The company's lead candidate, ARX-1796, is a proprietary oral formulation of Avibactam®, a recently FDA-approved broad-spectrum β-lactamase inhibitor. The company’s technology platform applies prodrug chemistry to existing intravenous-only antimicrobials to enable oral absorption of the active ingredient.